<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Avatar Trial Identifies New Treatment Route for Melanoma Patients

Melanoma accounts for approximately five percent of all skin cancer cases, yet it is responsible for nearly 75 percent of skin cancer-related deaths. The BRAF gene is frequently mutated in melanoma, leading to aberrant activation of an important growth pathway. Melanoma patients who receive treatment with targeted therapies that inhibit activated BRAF experience an initial response, but quickly relapse as their cancers find alternative pathways to grow and spread. Researchers at The Wistar Institute studied melanoma “escape routes” in the hope of finding combination treatments that prompt them to die. Their findings were published by the journal Clinical Cancer Research.

While early-stage melanoma can often be removed with surgery, a more advanced disease is much harder to treat. In recent years, newer types of immunotherapy and targeted therapies have shown great promise and have changed the treatment of this tumor type. Drugs that target the BRAF protein, such as vemurafenib (Zelboraf®) and dabrafenib (Tafinlar), as well as drugs that target the related MEK proteins, such as trametinib (Mekinist) and cobimetinib (Cotellic), have been shown to shrink tumors that test positive for BRAF mutation.

However after initial response, melanoma often escapes targeted treatments, prompting doctors to come up with a new therapeutic approach, combining BRAF and MEK inhibitors for increased antitumor efficacy. This combinatorial strategy showed promising results, with longer response times and less common side effects.

Unfortunately the BRAF/MEK pathway is not the only growth signaling melanoma is able to highjack. Escape routes have been documented, such as those downstream the NRAS and MAP2K1 oncogenes, which are frequently activated within tumor cells to overcome BRAF/MEK inhibition.

In a continuous effort to improve responses for patients who relapse after receiving a BRAF inhibitor, researchers at The Wistar Institute, led by Dr. Meenhard Herlyn, director of Wistar's Melanoma Research Center, have utilized rodent models as “patient avatars” to investigate and target the alternative growth pathways exploited by treatment resistant tumors.

Using this approach The Wistar Institute’s group of researchers was able to identify a possible new mechanism of resistance, involving the activation of a third growth promoting pathway, downstream the amplification of the MET oncogene in melanoma that have relapsed after treatment with BRAF inhibitors.

The targeted MET inhibitor capmatinib, previously considered ineffective for melanoma, was retested for its ability to halt the progression of disease in avatars from this specific subset of melanoma patients.

Capmatinib treated avatars showed significant tumor regression when the drug was used as single agent, however the results were only temporary, suggesting that an MET gene amplification is not the sole driver of growth in these tumors. However, when capmatinib was given in combination with encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor interfering with the BRAF pathway), the researchers observed complete and sustained tumor regression in all animals who received this combination.

For the successful development of targeted therapies it is paramount to identify patients which are most likely to benefit from a given drug treatment. One of the main goals of translational research for oncology is the discovery of biomarkers predictive of clinical efficacy. With the world’s largest collection of over 2,000 well-characterized patient-derived xenograft (PDX) models – large enough to be truly reflective of the patient population – Crown Bioscience enables drug discovery organizations to perform human surrogate Phase II-like mouse clinical trials, also known as HuTrials™, to identify suitable disease indications and discover and validate predictive biomarkers for their therapies. HuTrials can be used to position, or re-position, your drug in the marketplace.

At Crown Bioscience we can select the appropriate models to enrol in a HuTrial™ by using HuBase™, our curated database of HuPrime® PDXs. Most HuPrime® models are maintained in passage ready for clients’ projects. Crown’s capacity to perform large-scale studies, screening dozens of models in one single study, means that we can perform your HuTrial™ in months rather than years.

Contact us at busdev@crownbio.com to talk to our experts about how HuTrials can drive forward your drug development research.

Related Posts